Kymera Therapeutics Stock Price on December 11, 2024
| KYMR Stock | USD 42.02 1.20 2.94% |
Below is the normalized historical share price chart for Kymera Therapeutics extending back to August 21, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Kymera Therapeutics stands at 42.02, as last reported on the 27th of December, with the highest price reaching 42.33 and the lowest price hitting 39.29 during the day.
If you're considering investing in Kymera Stock, it is important to understand the factors that can impact its price. Kymera Therapeutics has Sharpe Ratio of -0.0413, which conveys that the firm had a -0.0413% return per unit of risk over the last 3 months. Kymera Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kymera Therapeutics' Mean Deviation of 2.53, risk adjusted performance of (0.06), and Standard Deviation of 3.28 to check out the risk estimate we provide.
As of 12/27/2024, Stock Based Compensation is likely to grow to about 45.3 M, while Total Stockholder Equity is likely to drop slightly above 278.6 M. . At this time, Kymera Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 12/27/2024, Price Earnings To Growth Ratio is likely to grow to 1.00, while Price Earnings Ratio is likely to drop (10.62). Kymera Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 21st of August 2020 | 200 Day MA 41.3036 | 50 Day MA 45.7592 | Beta 2.219 |
Kymera |
Sharpe Ratio = -0.0413
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KYMR |
Estimated Market Risk
| 3.32 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kymera Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kymera Therapeutics by adding Kymera Therapeutics to a well-diversified portfolio.
Price Book 2.9607 | Enterprise Value Ebitda (9.49) | Price Sales 30.1922 | Shares Float 44 M | Wall Street Target Price 58.7368 |
Related Headline
Monte Rosa Headline on 11th of December 2024
Monte Rosa Therapeutics Announces Closing of Global License ... by finance.yahoo.com
BOSTON, Dec. 11, 2024 -- Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, today announced the closing of the Companys previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, an
Kymera Therapeutics Valuation on December 11, 2024
It is possible to determine the worth of Kymera Therapeutics on a given historical date. On December 11, 2024 Kymera was worth 45.75 at the beginning of the trading date compared to the closed value of 45.02. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Kymera Therapeutics stock. Still, in general, we apply an absolute valuation method to find Kymera Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kymera Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Kymera Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 43.81 | 45.38 | 43.06 | 45.05 | 502,692 | |
12/11/2024 | 45.75 | 46.66 | 44.93 | 45.02 | 290,272 |
| 44.90 | 45.05 | 41.03 | 42.17 | 545,061 |
| Backtest Kymera Therapeutics | | | Kymera Therapeutics History | | | Kymera Therapeutics Valuation | Previous | Next |
Kymera Therapeutics Trading Date Momentum on December 11, 2024
| On December 12 2024 Kymera Therapeutics was traded for 42.17 at the closing time. The top price for the day was 45.05 and the lowest listed price was 41.03 . The trading volume for the day was 545.1 K. The trading history from December 12, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 6.33% . The trading delta at closing time against the current closing price is 10.40% . |
Kymera Therapeutics Fundamentals Correlations and Trends
By evaluating Kymera Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Kymera Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Kymera financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Kymera Therapeutics Stock history
Kymera Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Kymera is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Kymera Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Kymera Therapeutics stock prices may prove useful in developing a viable investing in Kymera Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 58.4 M | 44.4 M | |
| Net Loss | -139.3 M | -132.4 M |
Kymera Therapeutics Quarterly Net Working Capital |
|
Kymera Therapeutics Stock Technical Analysis
Kymera Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Kymera Therapeutics Period Price Range
Low | December 27, 2024
| High |
0.00 | 0.00 |
Kymera Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Kymera Therapeutics December 27, 2024 Market Strength
Market strength indicators help investors to evaluate how Kymera Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kymera Therapeutics shares will generate the highest return on investment. By undertsting and applying Kymera Therapeutics stock market strength indicators, traders can identify Kymera Therapeutics entry and exit signals to maximize returns
Kymera Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Kymera Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Kymera Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Kymera to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.47) | |||
| Treynor Ratio | (0.61) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.